Lab Angelus, Inc. — SEC Form D Filing
Lab Angelus, Inc. filed an SEC Form D on August 14, 2026, reporting $350K raised in Healthcare Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 14, 2026
- Amount reported
- $350K
- Round stage
- Seed
- Industry
- Healthcare Technology
- Website
- https://labangelus.com/
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Many cancer patients eligible for molecular profiling do not receive it due to operational inefficiencies and poor coordination in the workflow between community pathology labs, molecular reference labs, and treating oncologists. This leads to lost specimens, results, and patients falling through the gaps between diagnosis and treatment.
Solution
Lab Angelus builds digital infrastructure, starting with its flagship platform LabDispatch, to connect community pathology laboratories, molecular reference laboratories, and oncologists. This platform coordinates precision oncology testing into a single, traceable workflow to ensure patients receive timely and accurate diagnoses and treatments.
Why now
Precision oncology has advanced significantly, identifying specific mutations for targeted therapies, but the operational infrastructure (the 'plumbing') to deliver these advancements to all patients has not kept pace. Regulatory clarity around compliance (HIPAA, AKS) and the market's readiness for digital coordination in diagnostics now allow for such a platform to exist and scale compliantly.
Verdict
This cleared because the problem of fragmented pathology workflows in precision oncology is clearly defined and addressable with a digital solution, not because the company demonstrated market traction or unique technological breakthroughs. Investors were implicitly betting on the team's ability to navigate complex healthcare operational pathways and secure early partnerships within a highly regulated but underserved niche. The low raise amount ($350k) indicated an appetite for an operational-centric bet, accepting that a broader market capture or robust defensibility would be a much later-stage consideration.
Source: SEC EDGAR Form D filing